International Stroke Conference 2025  /  Risk Factors and Prevention Posters II  /  Short- and Long-term Effects of Statins in Cervical Artery Dissection
Logo

American Heart Association

  1
  0

Final ID: TP317

Short- and Long-term Effects of Statins in Cervical Artery Dissection

Abstract Body: Background:
Whether statin therapy should be prescribed for the prevention of subsequent events in patients with cervical artery dissection (CeAD) is unclear. We aimed to investigate the association of statin therapy with CeAD recurrence and cerebro/cardiovascular events in patients with CeAD.
Methods:
Single-center cohort-based study conducted at the University Hospital Basel (EKNZ PB-2016-00547) including patients with CeAD from January 1994 to February 2024. The co-primary outcomes were (i) recurrent CeAD and (ii) major adverse cerebro/cardiovascular events (MACE), comprising any stroke, myocardial infarction, cardiovascular death, and peripheral artery disease, both at (i) three months after CeAD onset and (ii) the longest available follow-up. We analyzed the outcomes using unadjusted, adjusted, and double-robust Cox regression and presented the results as hazard ratio (HR) estimates with 95% confidence intervals ([CI]).
Results:
In total, 324 of 348 (93%) patients (median age 45 years, 42% female, 21% statin users) were eligible for the three-month and 288 (89%) for the long-term follow-up analyses, with a median follow-up time of 5.6 years. After three months, recurrent CeAD occurred in 4 patients and MACE in 13, all of which were strokes within the vascular territory of the initially dissected artery. During long-term follow-up, recurrent CeAD occurred in 21 patients and MACE in 27, comprising 22 strokes, 3 myocardial infarctions, 1 cardiovascular death, and 3 cases of peripheral artery disease. After 3 months, there was no clear evidence of a difference in the hazard for recurrent CeAD (HRadjusted=6.08 [95% CI 0.60-61.58]) and MACE (HRadjusted=0.57 [95% CI 0.12-2.60]) between patients with and without statin therapy. During long-term follow-up, there was also no clear evidence of a difference in the hazard for recurrent CeAD (HRadjusted=2.10 [95% CI 0.60-7.37]) and MACE (HRadjusted=1.96 [95% CI 0.85-4.52]) between the groups.
Conclusions:
In patients with CeAD, statin therapy does not seem to be associated with CeAD recurrence or MACE in the short- or long-term.
  • Kaufmann, Josefin Emelie  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Wagner, Benjamin  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Katan, Mira  ( University Hospital of Basel , Basel , Switzerland )
  • Fischer, Urs  ( Inselspital, University Hospital Be , Freiburgstrasse , Switzerland )
  • Lyrer, Philippe  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Traenka, Christopher  ( Univers. Altersmedizin Felixplatter , Basel , Switzerland )
  • Engelter, Stefan  ( University Basel , Basel , Switzerland )
  • Brunner, Eveline  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Boos, Lukas  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Fischer, Sandro  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Gensicke, Henrik  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Zietz, Annaelle  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Polymeris, Alexandros  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Altersberger, Valerian  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
  • Fladt, Joachim  ( Department of Neurology and Stroke Center, University Hospital Basel and University of Basel , Basel , Switzerland )
    • Author Disclosures:
    Josefin Emelie Kaufmann: DO have relevant financial relationships ; Researcher:Goldschmidt Jacobson Foundation:Past (completed) | Benjamin Wagner: DO NOT have relevant financial relationships | Mira Katan: DO have relevant financial relationships ; Advisor:BMS:Past (completed) ; Research Funding (PI or named investigator):BRAHMS Thermofisher Scientific:Active (exists now) ; Research Funding (PI or named investigator):Swiss National Science Foundation:Active (exists now) | Urs Fischer: DO have relevant financial relationships ; Research Funding (PI or named investigator):Swiss National Science Foundation (fees paid to institution):Active (exists now) ; Other (please indicate in the box next to the company name):President Elect European Stroke Organisation:Active (exists now) ; Other (please indicate in the box next to the company name):President Swiss Neurological Society:Active (exists now) ; Consultant:Boehringer Ingelheim (fees paid to institution):Active (exists now) ; Consultant:CSL Behrling (fees paid to institution):Active (exists now) ; Consultant:Medtronic (fees paid to institution):Active (exists now) ; Research Funding (PI or named investigator):Boehringer Ingelheim (fees paid to institution):Active (exists now) ; Research Funding (PI or named investigator):Rapid Medical (fees paid to institution):Active (exists now) ; Research Funding (PI or named investigator):Phenox (fees paid to institution):Active (exists now) ; Research Funding (PI or named investigator):Penumbra (fees paid to institution):Active (exists now) ; Research Funding (PI or named investigator):Stryker (fees paid to institution):Active (exists now) ; Research Funding (PI or named investigator):Medtronic (fees paid to institution):Active (exists now) ; Research Funding (PI or named investigator):Swiss Heart Foundation (fees paid to institution):Active (exists now) | Philippe Lyrer: No Answer | Christopher Traenka: DO NOT have relevant financial relationships | Stefan Engelter: No Answer | Eveline Brunner: DO NOT have relevant financial relationships | Lukas Boos: DO NOT have relevant financial relationships | Sandro Fischer: No Answer | Henrik Gensicke: No Answer | Annaelle Zietz: DO NOT have relevant financial relationships | ALEXANDROS POLYMERIS: DO NOT have relevant financial relationships | Valerian Altersberger: DO NOT have relevant financial relationships | Joachim Fladt: DO NOT have relevant financial relationships
Meeting Info:

International Stroke Conference 2025

2025

Los Angeles, CA

Session Info:

Risk Factors and Prevention Posters II

Thursday, 02/06/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
Combined use of cardioprotective glucose-lowering drugs and statins in individuals with type 2 diabetes is associated with the lowest risk of all-cause mortality

Ternhamar Tummas, Johansen Mia, Nordestgaard Borge, Afzal Shoaib

Diagnostic and Therapeutic Challenges with Spinal Cord Infarction: A Real-World Experience from a Comprehensive Stroke Center

Shakeel Hassan Abdullah, Saim Muhammad, Singh Romil, Cerejo Russell

More abstracts from these authors:
Psycological sequelae in Cervical Artery Dissection patients - likely an underestimated risk

Svaerke Katrine, Engelter Sophia, Marugg Cilgia, Kaufmann Josefin Emelie, Rosenbaum Sverre, Brunner Eveline, Christensen Hanne, Engelter Stefan, Traenka Christopher

Statin Use in Cervical Artery Dissection and Subsequent Ischemic Stroke

Lodhi Omair Ul Haq, Zubair Adeel, Almajali Mohammad, Affan Muhammad, Yaghi Shadi, Shu Liqi, Chung Natali, Leon Guerrero Christopher, Engelter Stefan, Kaufmann Josefin Emelie, Traenka Christopher, Kam Wayneho

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.

   Rate this abstract  (Maximum characters: 500)